ACT Brief: Protocol Interpretation as Startup Bottleneck, Plausible Mechanism Framework, and Real-Time Trial Tracking Systems

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• Research from Tufts CSDD and CRIO identified protocol interpretation and source document preparation as an understudied bottleneck in study startup that may hold significant efficiency opportunities. Sites struggle with inconsistent documentation, misaligned procedures and timelines, and contradictory eligibility criteria, yet this process has received minimal attention despite potentially unlocking major improvements in activation speed.
• In part one of a new video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, explained how the plausible mechanism framework reshapes development timelines for individualized therapies. First-in-human studies can now serve as pivotal trials, giving sponsors earlier clarity on evidence needed for approval and dramatically compressing traditional development cycles.
• In a new Q&A from Pharmaceutical Executive, Deepak Prakash, VP of healthcare at Identiv, discussed how RFID and Bluetooth-enabled tracking technologies create continuous visibility across fragmented trial workflows. Real-time monitoring of samples, supply chain conditions, and patient compliance reduces manual reconciliation, improves data integrity, and enables earlier intervention before problems compound across sites and logistics networks.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.